mProX™ Human KLRD1 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human KLRD1 Stable Cell Line (S01YF-1023-PY148). Click the button above to contact us or submit your feedback about this product.
Taylor Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jordan Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 In fulminant type 1 diabetes, a notable reduction in the expression of KLRD1 (CD94), which is known to form a heterodimer with KLRC3 (NKG2E), was observed within NK-enriched cells when compared to healthy controls.
In NK-enriched cells, a significant reduction in KLRD1 (CD94) expression was observed in both fulminant type 1 diabetes (0.55 ± 0.09) and type 1A diabetes (0.55 ± 0.10) when compared to healthy controls, as determined by real-time PCR (1.00 ± 0.16, p = 0.0284, 0.0318), with values presented as mean ± SEM. Notably, a statistical significance of *p < 0.05 was identified in the comparisons.
Ref: Nakata, Shinsuke, et al. "Low gene expression levels of activating receptors of natural killer cells (NKG2E and CD94) in patients with fulminant type 1 diabetes." Immunology Letters 156.1-2 (2013): 149-155.
Pubmed: 24177169
DOI: 10.1016/j.imlet.2013.10.004
Research Highlights
Bai, Han. et al. "Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing." International immunopharmacology, 2023.
Amidst the global COVID-19 pandemic, Thymosin α1 (Tα1) emerged as a potential therapeutic option, yet with limited data available. Researchers recruited 33 symptomatic SARS-CoV-2-infected individuals and 11 healthy controls, comparing those with and without Tα1 treatment. Through comprehensive analysis, they discovered increased proportions of CD3+ KLRD1+ NKT and TBX21+ CD8+ NKT cells in COVID-19 patients with Tα1 treatment and healthy controls receiving it. Furthermore, Tα1 impacted gene expression and pathways associated with immune responses in TBX21+ CD8+ NKT cells. These findings suggest Tα1's potential efficacy in COVID-19 treatment by promoting NKT cell activity and TCR clone diversity.
Bai, Han. et al. "Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing." International immunopharmacology, 2023.
Pubmed:
37769533
DOI:
10.1016/j.intimp.2023.110983
Dou, Xiaowen. et al. "Upregulated CD8+ MAIT cell differentiation and KLRD1 gene expression after inactivated SARS-CoV-2 vaccination identified by single-cell sequencing" Frontiers in immunology, 2023.
Recent research has shown that the most effective approach in decreasing the spread of COVID-19 is through administering the SARS-CoV-2 vaccine. However, there is limited research on the effects of this vaccine on T cell subset differentiation and induced gene expressions. This study aims to use single-cell sequencing to analyze T cell dynamics and transcriptome gene expression following inoculation with an inactivated SARS-CoV-2 vaccine. Understanding these dynamics and expressions can provide valuable insight into the immune response to the vaccine.
Dou, Xiaowen. et al. "Upregulated CD8+ MAIT cell differentiation and KLRD1 gene expression after inactivated SARS-CoV-2 vaccination identified by single-cell sequencing" Frontiers in immunology, 2023.
Pubmed:
37654490
DOI:
10.3389/fimmu.2023.1174406
